AI Analysis | Feedback

Here are a few brief analogies for ACADIA Pharmaceuticals (ACAD):

• A focused biotech, like a specialized Biogen, for developing small molecule drugs for brain and nervous system disorders.
• Think of it as AbbVie's neuroscience division, but exclusively focused on discovering small molecule therapies for challenging brain conditions.

AI Analysis | Feedback

• NUPLAZID (pimavanserin): A commercialized drug used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
• Pimavanserin (pipeline): In phase 3 development for treating Alzheimer's disease psychosis and negative symptoms of schizophrenia.
• Trofinetide: A novel synthetic analog in phase 3 development for the treatment of Rett syndrome.
• ACP-044: A novel first-in-class non-opioid analgesic in phase 2 development for treating acute and chronic pain.
• ACP-319: A positive allosteric modulator of the muscarinic receptor in phase 1 development for treating schizophrenia and cognition in Alzheimer's.

AI Analysis | Feedback

ACADIA Pharmaceuticals (ACAD) primarily sells its pharmaceutical products to major pharmaceutical wholesalers and distributors. These companies then distribute the drugs to pharmacies, hospitals, and other healthcare providers, who in turn dispense them to individual patients.

The major customers for ACADIA Pharmaceuticals are typically large pharmaceutical wholesale distributors. Based on industry standards, these major distributors are likely to include:

• McKesson Corporation (MCK)
• Cencora (formerly AmerisourceBergen Corporation) (COR)
• Cardinal Health, Inc. (CAH)

AI Analysis | Feedback

• Lonza Group Ltd. (LONN)
• Thermo Fisher Scientific (TMO)
• Catalent Pharma Solutions, LLC (CTLT)
• Bachem AG (BANB)

AI Analysis | Feedback

Catherine Owen Adams, Chief Executive Officer

Ms. Owen Adams joined Acadia as Chief Executive Officer and a member of its Board of Directors in September 2024. She brings over 25 years of executive-level experience in the pharmaceutical industry. Prior to joining Acadia, she served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb (BMS), where she oversaw a $20 billion commercial business across Oncology, Cardiovascular, and Immunology, managing over 3,000 employees and significant product launches. Before her tenure at BMS, Ms. Owen Adams spent 25 years at Johnson & Johnson (J&J), holding various leadership roles including President, Janssen Immunology U.S. She began her career in R&D and manufacturing at AstraZeneca. Ms. Owen Adams currently serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company.

Mark Schneyer, Executive Vice President, Chief Financial Officer

Mr. Schneyer was promoted to Executive Vice President, Chief Financial Officer, in December 2021, having joined Acadia in May 2020 as Senior Vice President of Business Development and Chief Business Officer. In his role as CFO, he manages strategic finance, investor relations, accounting, business development, and information technology. Prior to Acadia, Mr. Schneyer was Vice President, Business Development for the Upjohn division at Pfizer Inc., where he spent several years in worldwide business development, leading various strategic transactions including licensing, acquisitions, divestitures, and collaborations. Before Pfizer, he worked as an investment banker at Lazard, advising healthcare sector boards and senior management. He was instrumental in Acadia's acquisition of CerSci Therapeutics in late 2020, which added a Phase 2 pain program to the pipeline.

Thomas Garner, Chief Commercial Officer

Mr. Garner serves as Acadia Pharmaceuticals' Chief Commercial Officer.

Jennifer J. Rhodes, Executive Vice President, Chief Legal Officer and Secretary

Ms. Rhodes joined Acadia in January 2024 as Executive Vice President, Chief Legal Officer and Secretary. Before Acadia, she held roles at Angion Biomedica Corp., including Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer, and Corporate Secretary. She also served as General Counsel, Corporate Secretary, Chief Compliance Officer, and Chief Business Officer at Adamas Pharmaceuticals, Inc. Earlier in her career, Ms. Rhodes was an attorney with Weil, Gotshal & Manges LLP.

Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development

Dr. Thompson is the Head of Research and Development at Acadia Pharmaceuticals.

AI Analysis | Feedback

ACADIA Pharmaceuticals (ACAD) faces several key risks to its business, primarily stemming from its reliance on a limited number of commercialized products and the inherent challenges of drug development in the central nervous system (CNS) disorder space.

1. Clinical Trial and Regulatory Risks for Pipeline Candidates: ACADIA's future growth is highly dependent on the successful development and regulatory approval of its pipeline products and the expansion of approved drug indications. The company has a history of clinical development setbacks, including the failure of pimavanserin in Phase 3 trials for negative symptoms of schizophrenia, leading to the discontinuation of further research for this indication. Additionally, pimavanserin faced rejections from the FDA for dementia-related psychosis and Alzheimer's disease psychosis. More recently, Trofinetide (DAYBUE), while approved in the U.S., received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) for Rett Syndrome in the European Union, hindering its international expansion prospects. These setbacks highlight the significant and ongoing risk associated with clinical trial outcomes and the stringent regulatory approval process, which can severely impact the company's growth strategy.
2. Dependence on Commercial Performance of Key Products: The company's financial stability and future growth are heavily reliant on the commercial success and market acceptance of its two primary marketed products, NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE (trofinetide) for Rett syndrome. NUPLAZID, for example, previously accounted for a large portion of the company's sales. Any factors affecting the sales of these drugs, such as increased competition, pricing pressures, changes in payer coverage or patient access, or unforeseen safety concerns, could significantly impact ACADIA's revenue and profitability. NUPLAZID also carries a Boxed Warning regarding an increased risk of death in elderly patients with dementia-related psychosis and a risk of QT prolongation, which requires careful monitoring and prescribing.
3. Intense Competition in the CNS Market: ACADIA operates in a highly competitive biopharmaceutical industry where many competitors possess greater resources, more experience in regulatory matters, and stronger pipelines. The CNS disorder market, including areas like Parkinson's disease psychosis, Rett syndrome, and other conditions ACADIA targets, faces competition from existing treatments (including off-label use of other drugs) and new therapies, such as emerging gene therapies. This intense competitive landscape poses a continuous threat to ACADIA's market share, pricing power, and ability to achieve sustained commercial success for its current and future products.

AI Analysis | Feedback

null

AI Analysis | Feedback

NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis (PDP)

Pimavanserin and Remlifanserin for Alzheimer's Disease Psychosis (ADP)

Trofinetide (DAYBUE) for Rett Syndrome

Pimavanserin for Negative Symptoms of Schizophrenia

AI Analysis | Feedback

ACADIA Pharmaceuticals (NASDAQ: ACAD) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and product advancements:

1. Continued Growth of NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis (PDP): ACADIA anticipates sustained growth for NUPLAZID, its treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company reported strong performance in Q4 2025 and has provided 2026 guidance indicating 10% to 14% growth over 2025 adjusted net sales. ACADIA aims for NUPLAZID to achieve blockbuster status, reaching $1 billion in annual sales by 2028. This growth is supported by underlying volume increases and a significant 30% expansion of its customer-facing sales teams, which were fully deployed in early 2026. Furthermore, the company is expanding its target physician list from approximately 7,000 to 11,000. Favorable patent judgments are also expected to preserve NUPLAZID's market exclusivity, reducing the threat of generic competition.

2. Increased Adoption and Expanded Reach of DAYBUE (trofinetide) for Rett Syndrome: DAYBUE, approved for Rett syndrome, is a significant growth driver for ACADIA. The company's Q4 2025 net sales for DAYBUE were strong, and its 2026 guidance projects 18% to 25% growth over 2025 sales. Key to this growth is the expansion into community physician settings within the U.S. and continued contributions from named patient supply programs outside the U.S. The launch of DAYBUE STIX, a new powder formulation, is expected to further broaden uptake and lead to an estimated 400 incremental patients by 2028. While there was a negative opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for trofinetide in the EU, ACADIA plans to seek reexamination, indicating ongoing efforts for international market expansion, although EU commercial sales are excluded from 2026 guidance.

3. Advancement of Remlifanserin (ACP-204) for Alzheimer's Disease Psychosis (ADP) and Lewy Body Dementia Psychosis (LBDP): ACADIA's pipeline asset, remlifanserin (formerly ACP-204), represents a substantial future revenue opportunity. Top-line results from the Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis are anticipated between August and October 2026. Remlifanserin has a projected peak sales potential of approximately $4 billion across its targeted indications, which include both Alzheimer's disease psychosis and Lewy Body Dementia Psychosis. The company also initiated a Phase 2 study of ACP-204 for Lewy Body Dementia in the third quarter of 2025.

4. Progress of ACP-101 for Prader-Willi Syndrome: The advancement of ACP-101, an investigational candidate for hyperphagia in Prader-Willi syndrome (PWS), offers another potential revenue stream. Enrollment of the last patient in the Phase 3 COMPASS PWS study for ACP-101 is anticipated in the fourth quarter of 2025, with top-line results expected in the first half of 2026. A successful outcome and subsequent approval would significantly contribute to ACADIA's revenue diversification.

AI Analysis | Feedback

Share Repurchases

• ACADIA Pharmaceuticals has not conducted any share repurchase programs over the last 3-5 years.

Share Issuance

• Common stock has been issued primarily through the exercise of stock options and units, totaling approximately $1.466 million in the three months ended March 31, 2023.
• The number of shares outstanding increased from 0.16 billion in 2021 to 0.168 billion in February 2026.
• The annual net issuance of stock was $25.777 million in 2023 and $6.845 million in 2024.

Inbound Investments

• No significant inbound investments by third-parties, such as strategic partners or private equity firms, have been reported within the last 3-5 years.
• The company has maintained a balance sheet with no long-term debt over the past five years.

Outbound Investments

• ACADIA Pharmaceuticals acquired Levo Therapeutics in June 2022, adding ACP-101 for the treatment of hyperphagia in Prader-Willi syndrome to its pipeline.

Capital Expenditures

• Capital expenditures were approximately $1.12 million in 2021, $0.00 in 2022, $40.05 million in 2023, and $0.523 million in 2024.
• Expected capital expenditures are $4.69 million for 2025 and $6.85 million for 2026.
• Capital expenditures primarily support ongoing operations, including administering clinical trials, marketing products, and investing in technology and facility infrastructure, with manufacturing activities generally outsourced.